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Abstract
The revised Society for Cardiovascular Angiography and Interventions classifications reflect graduation of severity within
each stage and pathway by which patients progress or recover. However, they are limited regarding the following: their
predictive role to guide therapy; escalation of therapy or referral; variability in diagnostic criteria and interpretation; presence
of other disease modifiers and confounders; variability of etiology and reversibility of cause; response to therapy and trajectory
to be taken into risk stratification; magnitude and phenotypes of end-organ damage. Thus, we need a modified risk score to
predict the necessity to escalate therapy and consider advanced therapies, such as mechanical circulatory support. Future
research on validation studies and reclassification analyses is needed.
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Background
In December 2021, the latest statement of the Society for
Cardiovascular Angiography and Interventions (SCAI) shock
stage classification for adult patients was endorsed by the
American College of Cardiology (ACC), American College of
Emergency Physicians (ACEP), American Heart Association
(AHA), European Society of Cardiology (ESC) Association
for Acute Cardiovascular Care (ACVC), International Society
for Heart and Lung Transplantation (ISHLT), Society of
Critical Care Medicine (SCCM), and Society of Thoracic
Surgeons (STS).1 Despite its recent publication, the consensus
in the field is that this latest strategy needs refinement.
The original 2019 SCAI Shock Stages rank the severity
of cardiogenic shock using the A, B, C, D, E scale.2 The initial
goal was to standardize the terminology used in the field.
However, the practical utility of this system to guide
management in a clinical setting has been challenging. While
the extremes of the scale (A, D, and E) are now relatively
agreed upon and recognized, the middle of the spectrum (B

and C) can be more difficult to identify and use. Importantly,
the current stages identify severity, but they lack actionable
terminology. To move classification systems forward, six
current limitations need to be addressed (Figure). Each
limitation includes a practical and simple solution that could
be used in a future scoring system.
Ideally, future scoring systems should not measure and
classify what was done but identify what needs to be done.
The ideal scoring system can guide physicians on when and
what type of care escalation is needed. Further, diagnostic and
prognostic accuracy and management targets could be
improved with additional standardization of variables and
expansion of criteria to include important factors, such as
etiology.

Conclusion
If these challenges in the current staging approach are
addressed and incorporated in future iterations of cardiogenic
shock classifications, the management of cardiogenic shock
will certainly move forward.
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Figure. Summary of the challenges to the current cardiogenic shock classification scheme.
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